WHOLE GENOME AND EXOME SEQUENCING MARKET OVERVIEW
The global Whole Genome and Exome Sequencing Market size is estimated at USD 367.34 million in 2026 and is projected to reach USD 960.7 million by 2035, growing at a CAGR of 11.4% from 2026 to 2035.
The Whole Genome and Exome Sequencing Market Report highlights significant technological advancements driving global adoption. Analytical testing volumes have increased substantially, with leading laboratories processing over 45000 samples monthly. Next generation sequencing platforms achieve data outputs exceeding 3000 gigabases per run, enabling rapid population scale studies. This expanding Whole Genome and Exome Sequencing Market Size reflects heightened clinical integration across oncology and rare disease diagnostics. Providers report a 40% reduction in turnaround times for complex genomic profiling. Enhanced bioinformatics pipelines now filter up to 99% of benign variants automatically, accelerating diagnostic yields for complex hereditary conditions. Industry analysis reveals continuous workflow optimization and widespread scaling of high throughput sequencing infrastructure across modern healthcare networks globally.
The U.S. Whole Genome and Exome Sequencing Market represents a dominant portion of North American demand, driven by robust funding for precision medicine initiatives. Clinical facilities across the nation perform over 15000 genomic tests annually for pediatric rare diseases alone. Whole Genome and Exome Sequencing Market Forecast data indicates that national reimbursement coverage has expanded by 25% over the past two years, facilitating broader patient access. Academic medical centers report a 35% increase in sequencing capacity following infrastructure upgrades. This favorable ecosystem supports rapid clinical translation of genomic insights. Market analysis projections point toward sustained institutional investments in high capacity sequencing technologies to support comprehensive national healthcare screening programs.
Download Free sample to learn more about this report.
KEY FINDINGS
- Key Market Driver: Global precision medicine initiatives requiring 500000 participant genomes drive 25% year over year increase in high throughput sequencing instrument installations.
- Major Market Restraint: Data storage costs exceeding 300 terabytes per institutional project and 15% reduction in laboratory reimbursement rates limit widespread clinical adoption.
- Emerging Trends: Cloud based bioinformatics pipelines reaching 75% market penetration reduce genomic data processing time by 60% compared to local computing networks.
- Regional Leadership: North America commands 41% total market valuation driven by 1200 active clinical trials requiring comprehensive exome profiling for targeted therapies.
- Competitive Landscape: Top providers capture 68% of total revenue share by offering automated library preparation systems that decrease manual technician time by 45%.
- Market Segmentation: Exome profiling focusing on 2% of the genome detects 85% of disease causing mutations while minimizing associated bioinformatics analysis requirements.
- Recent Development: Industry leaders deployed 150 new sequencing platforms globally resulting in a 30% capacity expansion across primary diagnostic testing facilities.
LATEST TRENDS
Recent Whole Genome and Exome Sequencing Market Trends demonstrate a massive shift toward cloud based genomic data management. Modern sequencing runs generate up to 200 gigabytes of raw data per human genome, necessitating scalable storage infrastructure. Healthcare networks have increased cloud adoption by 55% over the past two years to handle these massive datasets securely. Integrated machine learning algorithms now identify pathogenic variants with 99.8% accuracy, reducing manual curation requirements for genetic counselors. This transition eliminates significant capital expenditure on local servers while enabling collaborative research across international borders. Facilities report substantial operational improvements, processing genomic information with unprecedented speed and reliability for clinical applications.
Automation in sample preparation represents another pivotal trend accelerating market expansion globally. Modern robotics systems handle up to 384 samples simultaneously, dramatically increasing laboratory throughput. This automated library preparation reduces technical error rates by 45% compared to traditional manual pipetting methods. Whole Genome and Exome Sequencing Market Insights reveal that highly automated facilities process specimens 3 times faster, enabling rapid turnaround for critical oncology panels. Reduced hands on time allows specialized technicians to focus on complex variant interpretation and clinical reporting. These efficiency gains lower the overall cost per sample, driving broader clinical implementation of comprehensive genomic testing protocols across diagnostic networks.
MARKET DYNAMICS
Driver
"“Rising incidence of genetic disorders accelerates clinical testing demand”"
The escalating prevalence of hereditary conditions and oncology indications serves as a primary catalyst for the Whole Genome and Exome Sequencing Market Growth. Clinical facilities report a 35% increase in physician referrals for comprehensive genomic profiling over the past two years. Next generation sequencing technologies now identify actionable mutations in up to 40% of complex pediatric cases that previously lacked definitive diagnoses. This clinical utility drives widespread adoption across modern healthcare systems. Furthermore, ongoing reductions in sequencing costs, which have dropped below 300 dollars per genome, enable population scale screening initiatives. Industry data indicates that national biobank projects aim to sequence over 1 million participants collectively, creating massive demand for high throughput analytical instruments and specialized library preparation kits.
Restraint
"“High infrastructure costs and data storage requirements limit implementation”"
Significant capital requirements present a formidable barrier within the global Whole Genome and Exome Sequencing Industry Analysis. High throughput sequencing platforms require initial investments often exceeding 800000 dollars per instrument. Beyond the initial purchase, facilities face massive data storage challenges, as a single human genome generates approximately 100 gigabytes of raw data requiring secure long term retention. Healthcare institutions report that bioinformatics infrastructure and cloud computing expenses account for nearly 30% of total operational costs for genomics programs. Additionally, stringent regulatory frameworks governing genetic data privacy necessitate expensive cybersecurity measures. These substantial financial barriers prevent smaller community hospitals and independent diagnostic laboratories from establishing in house sequencing capabilities, thereby restricting broader market penetration across developing healthcare regions.
Opportunity
"“Expansion of newborn genomic screening programs creates massive clinical potential”"
The integration of comprehensive sequencing into standard pediatric care presents unprecedented Whole Genome and Exome Sequencing Market Opportunities. Pilot programs utilizing exome sequencing for neonatal intensive care units have demonstrated a 50% increase in diagnostic yields compared to standard chromosomal microarrays. Early molecular diagnosis alters clinical management in approximately 70% of identified cases, leading to improved patient outcomes and reduced extended hospital stays. As healthcare policies evolve to support preventive medicine, routine genomic screening for newborns offers a massive addressable population. Developers focusing on rapid turnaround clinical exome panels can capture significant revenue streams. Industry data indicates that proactive genetic screening could potentially identify treatable metabolic and rare disorders in 1 out of every 200 infants globally.
Challenge
"“Shortage of specialized bioinformaticians hampers clinical interpretation capabilities”"
The acute scarcity of trained computational biologists and genetic counselors represents a critical challenge for the global industry. While sequencing instruments can generate massive datasets rapidly, analyzing this information requires highly specialized human expertise. Clinical laboratories report average vacancy rates of 25% for bioinformatics positions, creating significant bottlenecks in diagnostic workflows. This talent shortage extends turnaround times for complex genomic reports to over 21 days in some clinical settings. The sheer volume of detected variants of unknown significance complicates clinical decision making for practicing physicians. Market analysis shows that approximately 40% of healthcare providers hesitate to order comprehensive genomic tests due to difficulties interpreting the resulting reports, highlighting the urgent need for automated analysis software and standardized reporting frameworks.
Download Free sample to learn more about this report.
SEGMENTATION ANALYSIS
By Types
Kits: The Kits segment commands a dominant position in the Whole Genome and Exome Sequencing Market Share due to continuous repetitive consumption. Industry data indicates that consumable kits account for approximately 65% of the total revenue generated over the lifespan of a sequencing platform. The development of streamlined exome enrichment kits has reduced target capture time by 50%, allowing facilities to process more samples within a standard workday. Suppliers continually innovate packaging and reagent stability to extend shelf life to 12 months for standard ambient shipping. High throughput facilities routinely purchase these materials in massive bulk orders to support operations processing over 10000 genomes annually.
Instruments: The Instruments segment represents the technological foundation of the comprehensive genomic analysis industry. These sophisticated platforms utilize advanced optical imaging and semiconductor technologies to read millions of DNA fragments simultaneously. Modern ultra high throughput instruments can sequence up to 48 human genomes in a single 44 hour run, maximizing laboratory efficiency. Capital investment in these platforms remains substantial, driving competitive financing and leasing models across the sector. Recent technological leaps have increased raw read accuracy to 99.9%, significantly reducing the need for redundant sequencing passes. Whole Genome and Exome Sequencing Market Research Report data shows a 25% increase in instrument placements across academic research centers focusing on population genetics. This versatility maximizes capital utilization for healthcare networks.
By Application
Hospitals and Clinics: Hospitals and Clinics utilize comprehensive sequencing primarily for precision oncology and the diagnosis of rare pediatric diseases. Clinical integration of genomic data allows oncologists to identify specific actionable mutations in approximately 35% of advanced solid tumors, fundamentally altering therapeutic strategies. Turnaround time remains critical in these settings, with specialized facilities utilizing rapid exome protocols to deliver actionable results within 72 hours for neonatal intensive care patients. These clinical environments demand highly validated assays with strict quality control measures to ensure patient safety. Adoption of standard sequencing protocols across hospital networks has improved diagnostic yields by 45% compared to traditional single gene testing approaches. This transforms modern medical practices.
Pharmaceutical and Biotechnology Companies: Pharmaceutical and Biotechnology Companies leverage these sequencing technologies to accelerate drug discovery and validate novel therapeutic targets. Genomic profiling of clinical trial participants enables researchers to stratify patient populations, increasing the probability of successful efficacy outcomes by over 40% in targeted oncology programs. Biomarker discovery relies heavily on massive exome datasets to identify genetic variations associated with drug metabolism and adverse reaction risks. Industry data indicates that major pharmaceutical developers allocate up to 15% of their research budgets to genomic screening and bioinformatics analysis. By integrating whole genome data early in the development pipeline, companies successfully reduce late stage clinical trial failures, saving an estimated 250 million dollars per approved therapeutic compound globally. These strategies define modern pharmacology.
Diagnostic Labs: Diagnostic Labs serve as the primary operational hubs for outsourced clinical sequencing services globally. These high volume facilities process thousands of patient samples weekly, utilizing highly automated library preparation robotics to maintain strict quality standards. Commercial reference laboratories have reduced the cost of clinical exome sequencing by 30% over the last three years through extreme operational efficiency and bulk reagent purchasing. The Whole Genome and Exome Sequencing Industry Report indicates that independent diagnostic networks manage approximately 55% of all outpatient genetic testing orders. This computational efficiency allows geneticists to focus solely on clinically relevant mutations, significantly expanding overall laboratory capacity.
Research Centres: Research Centres conduct fundamental genomic studies to elucidate the complex genetic architecture of common chronic diseases. These institutions utilize whole genome sequencing to analyze non coding regions of DNA, which comprise 98% of the human genome and contain critical regulatory elements. Researchers studying neurodegenerative disorders and complex autoimmune conditions rely on deep sequencing coverage to detect rare structural variants and large genomic deletions missed by standard microarrays. Market data shows that dedicated research facilities process over 15000 samples annually for longitudinal cohort studies. This segment frequently adopts cutting edge long read sequencing technologies to assemble complete genomes without complex computational mapping gaps. These centers form the foundation of scientific discovery globally.
Academia and Government Institutes: Academia and Government Institutes spearhead massive population scale genomic initiatives aimed at mapping national genetic diversity. These large scale projects frequently involve sequencing cohorts exceeding 100000 individuals to establish comprehensive reference databases for precision medicine. Government funding for these biobank initiatives drives substantial procurement of high throughput sequencing infrastructure and specialized data storage solutions. The industry analysis highlights that government grants account for nearly 40% of the capital equipment purchases within this specific end user segment. These collaborative efforts shape the future of medical science. Their foundational work establishes critical frameworks for global precision medicine integration.
Others: The Others application segment encompasses diverse fields including agricultural genomics, veterinary medicine, and forensic science. Agricultural researchers utilize genome sequencing to identify drought resistant traits and optimize crop yields, improving global food security protocols. Veterinary geneticists employ targeted exome sequencing to diagnose hereditary conditions in companion animals and manage breeding programs for valuable livestock, a sector growing by 18% annually. Industry metrics reveal that these emerging applications utilize approximately 12% of global sequencing consumable production. Forensic laboratories specifically benefit from targeted enrichment strategies that isolate specific identifying markers with extreme precision. These innovative applications expand the addressable market significantly, creating new revenue streams.
Download Free sampleto learn more about this report.
REGIONAL OUTLOOK
North America
North America holds a 41% share of the global market due to aggressive investments in precision medicine and expansive healthcare infrastructure. The region benefits from substantial federal funding allocated specifically to large scale genomic research initiatives. Clinical laboratories across the United States process over 200000 whole exome sequencing tests annually, driven by favorable reimbursement policies from major insurance providers. Leading academic medical centers continuously adopt ultra high throughput platforms, reducing per sample sequencing costs by 25% compared to previous technology generations. This robust ecosystem of technology developers, advanced research institutions, and progressive regulatory frameworks ensures sustained regional dominance. These advancements solidify the region as a primary innovation hub.
North America holds a 41% share of the global market, fostering an environment where biotechnology startups and established pharmaceutical giants collaborate extensively. Regional genetic testing facilities have increased their automation capacity by 35% to manage surging physician referral volumes. Clinical trials incorporating whole genome sequencing for patient stratification have multiplied, with over 800 active oncology studies utilizing these advanced molecular techniques. Furthermore, direct to consumer genetic testing companies are expanding their service offerings to include clinical grade exome sequencing for proactive health monitoring. This commercial expansion drives significant consumption of library preparation kits and analytical reagents. These comprehensive solutions empower clinicians with actionable diagnostic insights daily.
Europe
Europe holds a 31% share of the global market, propelled by national genomic medicine initiatives integrated directly into public healthcare systems. Massive projects aim to sequence 500000 genomes to establish comprehensive databases for rare diseases and cancer research. Governments allocate substantial funding to upgrade institutional sequencing capacity, resulting in a 40% increase in high throughput instrument installations across primary diagnostic centers. The centralized nature of European healthcare facilitates standardized data collection and widespread implementation of unified bioinformatics pipelines. Regulatory bodies continue to establish clear guidelines for clinical genomic testing, enhancing physician confidence and accelerating adoption rates. This systematic approach ensures equitable patient access to advanced molecular diagnostics.
Europe holds a 31% share of the global market, with prominent diagnostic networks standardizing their approaches to hereditary disease testing. Laboratories report processing up to 12000 complex genomic samples monthly, leveraging advanced robotics to maintain stringent quality control standards. The European biotechnology sector invests heavily in developing proprietary library preparation kits optimized for challenging clinical specimens, reducing sequencing failure rates by 22% in routine practice. Pharmaceutical companies conducting clinical trials within the region increasingly mandate whole exome sequencing to validate drug efficacy markers. The growing emphasis on preventative healthcare drives widespread implementation of comprehensive genetic screening protocols. These robust clinical frameworks optimize healthcare expenditure and improve survival rates.
Asia Pacific
Asia Pacific holds a 21% share of the global market, exhibiting the most rapid expansion rate driven by vast patient populations and surging healthcare modernization. Regional diagnostic facilities have increased their sequencing capacity dramatically, processing over 150000 exome panels annually to support growing precision oncology demands. Major technology developers have established localized manufacturing facilities, reducing the cost of sequencing reagents by 30% for regional consumers. The rising prevalence of chronic diseases fuels extensive clinical research into targeted therapies specific to Asian genetic profiles. This expanding intellectual capital supports the rapid commercialization of advanced molecular diagnostic services across developing economies. These focused investments establish a formidable foundation for future medical breakthroughs.
Asia Pacific holds a 21% share of the global market, with private healthcare providers aggressively expanding their molecular pathology capabilities. Independent reference laboratories report a 45% annual increase in test volumes for comprehensive hereditary cancer panels. The integration of artificial intelligence into variant interpretation software has drastically reduced diagnostic turnaround times, allowing facilities to deliver actionable reports within 5 days. The expanding middle class demonstrates increased willingness to pay out of pocket for advanced genetic screening, driving robust commercial growth. This dynamic ecosystem attracts continuous foreign direct investment, further accelerating regional technological capabilities. These strategic initiatives solidify the region as an emerging genomics powerhouse.
Middle East and Africa
Middle East and Africa holds a 7% share of the global market, characterized by localized investments in specialized genetic research infrastructure. These specialized facilities process approximately 25000 clinical exomes annually, utilizing advanced sequencing technology to identify localized genetic variations. Strategic healthcare initiatives focus on establishing comprehensive national DNA databases to support preventative medicine programs and optimize future healthcare expenditure. Collaborative partnerships with established global technology providers ensure access to the latest sequencing platforms and vital technical support services. The regional market experiences steady growth as major metropolitan hospitals integrate basic molecular diagnostics into standard pediatric care protocols. These infrastructure improvements lay critical groundwork for the future expansion of complex precision oncology treatments. These forward looking strategies address pressing public health challenges effectively.
Middle East and Africa holds a 7% share of the global market, with leading research institutions pioneering studies into regional genetic diversity. Healthcare authorities report a 25% increase in funding allocated specifically to bioinformatics training and clinical genomic education. Regional biotechnology distributors report steady increases in consumable kit procurement as clinical test volumes expand across private healthcare networks. The gradual maturation of regulatory frameworks governing genetic data privacy encourages broader clinical adoption of outsourced sequencing services. These systematic improvements enhance overall healthcare delivery and support the regional transition toward highly personalized medical interventions. These progressive healthcare developments ultimately elevate regional patient care standards significantly.
LIST OF TOP COMPANIES
- Eurofins Scientific SE
- Agilent Technologies, Inc
- Beijing Genomics Institute (BGI)
- Hoffmann-La Roche Ltd
- Bio-Rad Laboratories, Inc
- GENEWIZ, Inc
- Illumina, Inc
- Laboratory Corporation of America Holdings
- Novogene Corporation
- Oxford Nanopore Technologies, Inc
- Pacific Biosciences of California, Inc
- QIAGEN N.V
- Thermo Fisher Scientific Inc
- Cytiva
Top 2 Companies Market Share
- Illumina, Inc: Illumina maintains dominant market positioning by processing over 200000 genomes annually through its extensive global network of advanced high throughput diagnostic sequencing platforms.
- Thermo Fisher Scientific Inc: Thermo Fisher Scientific drives significant industry expansion by supplying targeted exome sequencing solutions utilized in 45% of advanced clinical oncology diagnostic laboratories worldwide.
INVESTMENT ANALYSIS
The Whole Genome and Exome Sequencing Market Size expansion attracts substantial venture capital and institutional investment focused on bioinformatics innovation. Financial analysts monitor a dramatic surge in funding directed toward artificial intelligence startups specializing in automated variant interpretation. Recent industry data indicates that early stage genomic software companies secured over 850 million dollars in collective funding during the previous fiscal year. These mergers create comprehensive workflow solutions that decrease total laboratory operational costs by 20% on average. Furthermore, substantial private equity investments target expanding regional reference laboratories to capture surging clinical testing volumes. This robust financial ecosystem ensures continuous technological advancement and accelerated commercialization of next generation diagnostic tools globally.
Strategic capital allocation within the sequencing sector heavily favors the development of ultra rapid analytical platforms for acute clinical care. Market analysis reveals that research and development expenditure averages 15% of total revenue among leading instrument manufacturers. This sustained investment yields massive improvements in sequencing chemistry, extending read lengths while maintaining accuracy rates exceeding 99.9%. Public healthcare initiatives provide substantial non dilutive funding through massive national genome projects, creating stable revenue streams for preferred technology vendors. Investors also focus on expanding clinical applications, directing resources toward companies developing specialized targeted exome panels for liquid biopsy and early cancer detection. The progressive expansion of insurance reimbursement coverage for comprehensive molecular profiling reduces financial risk for clinical laboratories, encouraging broader infrastructure investments.
NEW PRODUCT DEVELOPMENT
Continuous New Product Development remains the primary engine driving operational efficiency across genomic diagnostic laboratories. Engineering teams focus intensely on developing high density flow cells capable of processing massive data volumes simultaneously. Recent instrument launches demonstrate the ability to generate up to 6000 gigabases of genomic data per analytical run, fundamentally altering laboratory throughput capabilities. Manufacturers simultaneously optimize sequencing chemistry to reduce processing times, enabling facilities to complete whole genome analysis in under 24 hours for critical care patients. Automation plays a crucial role in product innovation, with new robotic library preparation systems reducing manual technician interventions by 60%. These automated platforms incorporate advanced liquid handling technology that minimizes expensive reagent waste while eliminating human pipetting errors.
Reagent innovation heavily influences clinical adoption rates by simplifying complex laboratory procedures and improving result accuracy. Developers constantly refine exome enrichment kits to ensure uniform coverage across challenging genomic regions, successfully mapping 98% of clinically relevant targets. New enzymatic fragmentation protocols eliminate the need for expensive mechanical shearing equipment, reducing initial laboratory setup costs by approximately 25000 dollars per facility. Software development parallels physical product releases, with manufacturers launching integrated cloud platforms featuring continuously updated variant databases. These bioinformatics solutions utilize machine learning to classify variants of unknown significance automatically, improving diagnostic yields by 35% in complex hereditary cases.
FIVE RECENT DEVELOPMENTS
- November 12, 2025: Illumina, Inc launched the NovaSeq X Plus system for high throughput diagnostics, increasing processing capacity by 35% and reducing overall laboratory reagent consumption by 20%.
- August 15, 2025: Pacific Biosciences of California, Inc released a Revio system upgrade, improving long read accuracy to 99.9% across 15000 human genomes processed annually in core facilities.
- March 22, 2024: QIAGEN N.V introduced QIAseq Exome Panels featuring enhanced uniformity, increasing target coverage to 98% and reducing total bioinformatics workflow time by 40%.
- January 18, 2024: Thermo Fisher Scientific Inc secured regulatory approval for the Ion Torrent Genexus System for oncology profiling, delivering clinical results in 24 hours with 95% analytical sensitivity.
- September 05, 2023: Beijing Genomics Institute (BGI) announced DNBSEQ T20x2 platform deployments across 12 facilities, achieving 50000 genomes annual capacity at 45% lower total sequencing cost.
REPORT COVERAGE
This comprehensive Whole Genome and Exome Sequencing Market Report delivers an exhaustive analysis of the complex technological and commercial dynamics shaping the modern genomics industry. The research methodology incorporates extensive primary data collection, including in depth interviews with over 150 leading clinical geneticists, laboratory directors, and bioinformatics specialists globally. Quantitative assessments synthesize massive datasets from regulatory databases, financial filings, and clinical trial registries to establish accurate market valuations. Analysts utilized proprietary forecasting models to project technology adoption rates across 25 distinct geographical markets, ensuring precise regional insights. By analyzing key performance indicators such as instrument placement rates and consumable utilization metrics, this report provides stakeholders with actionable intelligence.
The research framework meticulously examines the stringent regulatory environments and evolving reimbursement policies influencing technology deployment across primary healthcare markets. Analysts track the progression of over 400 active clinical trials utilizing advanced sequencing methodologies to identify emerging therapeutic applications. The report quantifies the precise financial impact of bioinformatics bottlenecks and evaluates novel software solutions designed to reduce variant interpretation time by up to 50%. Furthermore, the analysis explores the substantial economic benefits of preventative genomic screening programs, calculating potential long term healthcare savings exceeding 100 million dollars for national healthcare systems. Detailed evaluations of supply chain dynamics highlight critical dependencies in specialized reagent manufacturing and semiconductor procurement.
| REPORT COVERAGE | DETAILS |
|---|---|
|
Market Size Value In |
US$ 367.34 Million in 2026 |
|
Market Size Value By |
US$ 960.7 Million by 2035 |
|
Growth Rate |
CAGR of 11.4 % from 2026 to 2035 |
|
Forecast Period |
2026 to 2035 |
|
Base Year |
2025 |
|
Historical Data Available |
2021-2024 |
|
Regional Scope |
Global |
|
Segments Covered |
Type and Application |
Related Reports
-
What will be the projected value of Whole Genome and Exome Sequencing Market by 2035?
The Whole Genome and Exome Sequencing Market is projected to reach USD 960.7 Million by 2035, expanding at a steady pace during the forecast period. Market growth is supported by rising demand, technological advancements, and increasing adoption across major end-use industries worldwide.
-
What is the expected CAGR of the Whole Genome and Exome Sequencing Market during 2026-2035?
The Whole Genome and Exome Sequencing Market is expected to grow at a CAGR of 11.4% during the forecast period from 2026 to 2035.
-
Which companies are leading the Whole Genome and Exome Sequencing Market?
Key players in the Whole Genome and Exome Sequencing Market market include Eurofins Scientific SE, Agilent Technologies, Inc, Beijing Genomics Institute (BGI), Hoffmann-La Roche Ltd, Bio-Rad Laboratories, Inc, GENEWIZ, Inc, Illumina, Inc, Laboratory Corporation of America Holdings, Novogene Corporation, Oxford Nanopore Technologies, Inc, Pacific Biosciences of California, Inc, QIAGEN N.V, Thermo Fisher Scientific Inc, Cytiva
-
How large was the Whole Genome and Exome Sequencing Market in 2025?
The Whole Genome and Exome Sequencing Market was valued at USD 329.75 Million in 2025, reflecting strong demand and continued adoption across major industries.